20 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 15 with minor changes only.
Primary completion pushed from Dec 5, 2028 to Mar 6, 2031
Also in this update: Study completion pushed from Jun 18, 2030 to Sep 16, 2032
AmgenPhase 1/2 NCT07134088 Registry history of NCT07134088 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 28, 2028 to Jan 1, 2030
Also in this update: Study completion pushed from Jul 28, 2028 to Feb 1, 2032
AmgenPhase 1 NCT07403721 Registry history of NCT07403721 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 12 → 20 locations
AmgenPhase 3 NCT07598825 Registry history of NCT07598825 on ClinicalTrials.gov (opens the registry)
Reclassified as terminated (was completed)
AmgenPhase 1 NCT05800964 Registry history of NCT05800964 on ClinicalTrials.gov (opens the registry)
Recruitment opened
AmgenPhase 1 NCT07811999 Registry history of NCT07811999 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Enrollment increased: 17 → 21 participants
AmgenPhase 3 NCT05565560 Registry history of NCT05565560 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion moved earlier from Sep 29, 2027 to Aug 30, 2027
AmgenPhase 3 NCT07226765 Registry history of NCT07226765 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Dec 22, 2027 to Nov 17, 2027; Primary completion moved earlier from Sep 29, 2027 to Aug 25, 2027
AmgenPhase 2 NCT07441252 Registry history of NCT07441252 on ClinicalTrials.gov (opens the registry)
Trial completed
AmgenPhase 1 NCT06585462 Registry history of NCT06585462 on ClinicalTrials.gov (opens the registry)
Trial completed
AmgenPhase 1 NCT07545226 Registry history of NCT07545226 on ClinicalTrials.gov (opens the registry)
Trial completed
AmgenPhase 1 NCT07229157 Registry history of NCT07229157 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 10, 2029 to Aug 10, 2029
AmgenPhase 2 NCT06745323 Registry history of NCT06745323 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 71 → 75 locations
AmgenPhase 3 NCT07388498 Registry history of NCT07388498 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 139 → 34 locations
AmgenPhase 3 NCT03937154 Registry history of NCT03937154 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 119 → 11 locations
AmgenPhase 3 NCT03836040 Registry history of NCT03836040 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 69 → 81 locations
And 1 more change in the last 30 days
AmgenPhase 3 NCT07614776 Registry history of NCT07614776 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 45 → 53 locations
AmgenPhase 3 NCT07575399 Registry history of NCT07575399 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 37 → 45 locations
AmgenPhase 3 NCT07684144 Registry history of NCT07684144 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 87 → 92 locations
AmgenPhase 3 NCT07684235 Registry history of NCT07684235 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 13 locations
AmgenPhase 2 NCT06987539 Registry history of NCT06987539 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-13 | NCT07871409 Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living… | Phase 3 | Not Yet Recruiting |
| 2026-10-08 | NCT07866066 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-01 | NCT07851220 A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Phase 3 | Recruiting |
| 2026-09-22 | NCT07832799 Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made… | Phase 1 | Not Yet Recruiting |
| Phase 1 | 24 | |
| Phase 1/2 | 4 | |
| Phase 2 | 13 | |
| Phase 3 | 50 | |
| Phase 4 | 7 |
Lung Cancer (22) · Obesity (16) · Small Cell Lung Cancer (14) · Heart Disease (8) · Non-Small Cell Lung Cancer (NSCLC) (8) · Diabetes (7) · Prostate Cancer (7) · Type 2 Diabetes (7) · Acute Lymphoblastic Leukemia (ALL) (5) · Leukemia (5)